EBITDA CAGR: N/A

EBITDA CAGR uses clean operating EBITDA derived from reported operating income plus depreciation and amortization.

Over the past 12 months, EBITDA CAGR is N/A. EBITDA CAGR shows how the company's operating profitability has grown before depreciation and amortization. This reflects the growth of the core business's cash-operating earnings power, independent of capital-intensity and accounting depreciation choices.

CLNN EBITDA CAGR Chart

No data available

CLNN Quarterly EBITDA Growth (YoY)

EBITDA growth vs the same fiscal quarter in the prior fiscal year, last 25 comparable quarters.

EBITDA

CLNN Quarterly EBITDA

$-4.99M

Reported quarterly EBITDA; no daily interpolation. Q2 FY2026 (2026-06-30): $-4.99M.

-56.14% over 10Y

EBITDA CAGR History

No historical data available

Quarterly EBITDA: QoQ & YoY

Period	Period End	Value	QoQ Growth	YoY Growth
Q2 FY2026	2026-06-30	-$4.99M	-192.7%	+9.2%
Q1 FY2026	2026-03-31	-$1.71M	+75.2%	+53.5%
Q4 FY2025	2025-12-31	-$6.88M	-30.3%	+16.6%
Q3 FY2025	2025-09-30	-$5.28M	+3.9%	+28.7%
Q2 FY2025	2025-06-30	-$5.50M	-49.7%	+21.2%
Q1 FY2025	2025-03-31	-$3.67M	+55.5%	+58.3%

About Clene Inc.

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.

Salt Lake City, UT

78 employees

clene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert Etherington

View full financials